You missed my point. Acadia has a veto right that it can monetize by threatening a veto, and then withdraw the veto in exchange for cash and/or participation. Baldwix was concerned that this veto right precludes all new indications. I am of the view that is not the case, and instead translates into Acadia having the power to get participation in one or more new indications, with the positive outcome that Neuren can still proceed. I understand that is not how you think it will play out GIARC63. However, I will not be surprised if that is how the veto right is successfully addressed.
Pipeline-in-a-drug, page-138
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |